George Gilder would like us to feel seventeen again.
An emerging new technology known as “Regenerative Medicine,” could create a “new you” and it's a once-in-a-lifetime opportunity to get into one small, unknown company, that could see its shares soar up to 10x higher.
The Teaser
There is an entire cottage industry dedicated to selling us stuff that makes us feel young and rich.
George Gilder has been called a “technology prophet.” However, he is best known for penning bestselling books such as Sexual Suicide, The Israel Test, and his seminal work, Wealth and Poverty.
The Greenbull has covered and revealed some of his previous picks, including a “10x Graphene Stock” for “Next-Gen AI” and his “Convergence Plays” (Moonshot Stocks).
Most things sold to us as cures for old age and ailing bones are snake oil.
Is “New You” (regenerative) medicine any different?
George believes so, saying “The “New You” revolution will make miracle technologies like antibiotics look primitive in comparison“.
He explains that unlike conventional medicines, which use toxic chemicals that harm a patient’s immune system, “New You” technologies seek to repair or replace what’s damaged in the body without relying on invasive surgery, toxic drugs, radiation, or other invasive procedures.
What George is teasing here is a novel approach to replacing or “regenerating” human tissues and organs using stem cells.
One in Three
According to the Accrediting Agency for Biomedicine, approximately one in three Americans could benefit from regenerative medicine.
That's more than 110 million people!
Regenerative medicine is already being tested at some of the top hospitals in the world like Johns Hopkins, where it's being used to repair damaged heart muscle in patients with chronic heart failure, and Cedars Sinai, where it's being used on patients prone to heart disease.
So far, the results have been off the charts.
Some stem cell therapies have reported success rates as high as 80%.
George thinks he has found one company that has the potential to become the Pfizer of regenerative medicine and the price of its shares could explode 10x higher.
The Pitch
Everything we need to know about it has been packed into a special report called: The “New You” Revolution: Up to 10X Profits in Regenerative Medicine.
The report can be ours if we accept a 30-day preview to the “elite advisory service,” Gilder’s Moonshots.
This would set us back $995 for one year and includes a 30-day money-back guarantee, weekly emails with small caps and microcaps on the verge of breaking out, full access to six real-time moonshot model portfolios, and live conference calls with George, once every three months.
Regenerative Medicine's Ultimate Goal
Breakthroughs are rare in conventional medicine.
However, they have become a routine occurrence in the relatively new branch of regenerative medicine.
So much so that the ultimate goal has become total cardiac regeneration – the renewal of damaged heart tissues for a new heart.
George gives us a few examples of such advances, including a 48-year-old who suffered a near-fatal heart attack.
Dave suffered from something called “Ischemic cardiomyopathy.” A narrowing of the arteries causing damage to his heart muscle.
His doctor told him that he had only 12 months to live and referred him to a local hospice for end-of-life care.
That's when Dave heard about an experimental treatment being tested by a heart foundation.
With nothing to lose, he traveled to London, England, for a clinical trial. There he received injections of a special serum made from his own bone marrow to stimulate the regrowth of his failing heart cells.
Dave's heart function improved within days, and within just a few weeks, he recovered much of his strength.
Now, only a few months removed from receiving a diagnosis of certain death, Dave is on the road to total recovery.
Cardiac regeneration technology appears to be more than just hype and similar biotech stocks have made staggering gains:
As impressive as these gains are, one company with the know-how to implement these advanced cardiac treatments could present an even more lucrative opportunity.
Revealing George Gilder's “New You” Regenerative Medicine Stock
George's teaser is long on anecdotes and short on tangible clues.
But we managed to find a few injected here and there.
- It is a tiny company that licenses its cardiac technology to other biotech companies.
- The company is already working with centers in North America, Europe, the Middle East, and Asia, as well as partner companies around the world.
- It holds 17 unique patents and has a pipeline of over 30 licensed gene and cell therapies.
- It is listed on the OTC (over the counter) market.
This sounds like Orgenesis Inc. (OTC: ORGS).
- Orgenesis a global biotech company “working to unlock the full potential of its cell and gene therapy technologies and licensing collaborations.”
- The company has research centers in Belgium, Israel, and South Korea working to develop its cell and gene therapies.
- It currently holds 20 patents and has developed, purchased, or in-licensed more than 30 therapies.
- ORGS stock trades on the OTCQX, the highest tier of the OTC Market.
Make 10x Your Money?
It would be easy to dismiss Orgenesis.
After all, its stock is down nearly 50% year-to-date, and not a single one of its therapies has made it to market…yet.
However, is there more than meets the eye that has George believing it's on the brink of breaking out?
What George is getting worked up about, beyond the results of other regenerative medicine companies is the following:
- Orgenesis' POCare Platform promises to minimize the cost of producing cell and gene therapy products.
- Its business model of partnering with others for initial clinical development of licensed POCare Therapies lowers its development cost.
- A growing portfolio of patents and exclusive rights to therapies in the US and abroad.
This all sounds nice, but the reality is anything but.
Orgenesis appears to be running out of cash, with only $200K on hand and short-term maturities of convertible loans of nearly $2 million, as of September.
Year-to-date revenues aren't enough to cover the shortfall and the only way out appears to be diluting shareholders by selling shares, which will be harder after the Nasdaq delisting.
I will be the first to admit that asking me about biotech is like asking a blind man if a painting is beautiful. I don't know if what Orgenesis has is pure gold or copper wire.
From what I was able to gather from the financials, it's a falling knife that we would be wise to avoid unless you want your capital to get a haircut.
Quick Recap & Conclusion
- George Gilder is teasing an emerging new technology known as “Regenerative Medicine,” that is creating a once-in-a-lifetime opportunity to get into a small, unknown company, that could see its shares soar up to 10x higher.
- “Regenerative Medicine” is cell and gene therapy treatments that have reported success rates as high as 80%.
- Everything we need to know about one company that has the potential to become the Pfizer of regenerative medicine has been packed into a special report called: The “New You” Revolution: Up to 10X Profits in Regenerative Medicine. The report can be ours if we accept a 30-day preview to the “elite advisory service,” Gilder’s Moonshots for $995 for the first year.
- We were able to reveal George's pick for free as Orgenesis Inc. (OTC: ORGS).
- Based on it's financials, George's pick looks like a falling knife that could be on the verge of going under unless it receives an emergency capital infusion.
What is a better regenerative medicine stock? Let readers know your picks in the comments.